Multicenter clinical experience of real life Dalbavancin use in gram-positive infections | Zendy

Sabine Wunsch | Zendy; Robert Krause | Zendy; Thomas Valentin | Zendy; Juergen Prattes | Zendy; Oskar Janata | Zendy; A. Lenger | Zendy; Rosa BellmannWeiler | Zendy; Günter Weiß | Zendy; Ines ZollnerSchwetz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Multicenter clinical experience of real life Dalbavancin use in gram-positive infections

Author(s) -

Sabine Wunsch,

Robert Krause,

Thomas Valentin,

Juergen Prattes,

Oskar Janata,

A. Lenger,

Rosa BellmannWeiler,

Günter Weiß,

Ines ZollnerSchwetz

Publication year - 2019

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2019.02.013

Subject(s) - dalbavancin , medicine , tolerability , endocarditis , osteomyelitis , concomitant , surgery , infective endocarditis , adverse effect , vancomycin , staphylococcus aureus , biology , bacteria , genetics

Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as endocarditis, prosthetic joint infections (PJI) or osteomyelitis. Clinical data are limited in these settings.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research